Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression - Yahoo Finance

Submitted by Anonymous (not verified) on Mon, 07/29/2019 - 12:00

Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression  Yahoo FinanceREL-1017 is a novel NMDA receptor antagonist in development as a rapidly acting oral agent for the treatment of depression. NEW YORK, July 29, 2019 ...